During the corresponding time, Inspiremd Inc recorded a revenue increase by 34.88 % year on year, sequentially revenue fell by -34.09 %. While revenue at the Inspiremd Inc 's corporate clients
Inspiremd Inc's Comment on Sales, Marketing and Customers
The company serves U.S. interventionalists and markets its product, CGuard Prime, primarily in the U.S. and Europe. It targets growth markets and new territories, focusing on interventionalists transitioning from carotid endarterectomy (CEA) to carotid artery stenting (CAS) and transcarotid artery revascularization (TCAR). The company markets and sells CGuard Prime through a direct sales organization of approximately 30 sales and clinical support personnel in the U.S. It collaborates with leading physicians and key opinion leaders to support marketing efforts and participate in clinical studies. The company initially launched CGuard EPS in CE-marked countries in 2015 and fully launched it in Europe in September 2015, utilizing local distribution partners and internal sales initiatives to expand geographic coverage and clinical specialty reach. CGuard Prime is positioned as a second-generation stent with positive patient outcomes, with the goal of becoming the standard of care for treating carotid artery disease in the U.S. The company is also evaluating CGuard Prime in TCAR-based clinical programs, including the CGUARDIANS II pivotal trial.
In an exciting development for the medical technology landscape, InspireMD, Inc. (NASDAQ: NSPR), a trailblazer in carotid stenting solutions, has announced a strategic partnership with NAMSA, a renowned global MedTech Contract Research Organization (CRO). This collaboration is set to usher in the CGUARDIANS II pivotal clinical trial for the CGuard Prime 80 cm Carotid Stent System, a groundbreaking innovation aimed at improving patient outcomes in Transcarotid Artery Revascularization (TCAR) procedures. The Significance of TCARTCAR has emerged as a revolutionary technique in the management of carotid artery stenosis, which significantly increases the risk of stroke. This minimally invasive procedure not only ...
In recent developments concerning the prevention of stroke, InspireMD, Inc. has announced the approval of their Investigational Device Exemption (IDE) application by the U.S. Food and Drug Administration (FDA) for their forthcoming CGUARDIANS II pivotal study. This study will specifically evaluate the effectiveness and safety of InspireMD s CGuard Prime 80cm Carotid Stent System during transcarotid revascularization (TCAR) procedures. Given the significance of such advancements in medical devices, this article aims to outline and interpret the key aspects of this development, placing a spotlight on transcarotid revascularization and its implications in stroke prevention.Carotid artery stenting is an establi...
InspireMD, a renowned medical device company specializing in innovative stents and embolic protection devices, recently presented the remarkable findings of its C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial at the LINC 2024 conference. With a primary endpoint event rate of just 1.95% within twelve months post-procedure, the results reveal a significant breakthrough for carotid stenting and embolic protection. In this article, we outline the key facts surrounding InspireMD s groundbreaking achievement and assess its profound implications for the company s future prospects.Facts:1. Positive Results from the C-GUARDIANS U.S. IDE Clinical Trial:The C-GUARDIANS study, designed to evaluate...
Carotid artery disease poses a significant threat to the cardiovascular health of individuals worldwide. With the aim of preventing ischemic strokes and improving patient outcomes, researchers and medical device companies have been actively engaged in developing innovative neuroprotection systems. InspireMD, a leading medical technology company, has recently appointed principal investigators for the C-GUARDIANS II clinical trial of their SwitchGuard Neuroprotection System. This article delves into the development of SwitchGuard, its compatibility with both Carotid Artery Stenting (CAS) and Transcarotid Artery Revascularization (TCAR) procedures, and its potential to revolutionize carotid implant and platform...
InspireMD Collaborates with Jacobs Institute to Pave the Way for Advancements in Stroke Treatment Medical device company InspireMD recently announced a groundbreaking strategic agreement with the renowned Jacobs Institute to conduct a pioneering Early Feasibility Study (EFS). The study aims to evaluate the effectiveness of CGuard Embolic Prevention System (EPS) in treating acute stroke patients who also suffer from tandem lesions. This collaboration between InspireMD and the influential Jacobs Institute is expected to bring forth significant advancements in stroke treatment. The EFS will enroll a total of 15 acute stroke patients across three reputable medical sites within the United States. The sele...
Inspiremd Inc’s Comment on Sales, Marketing and Customers
The company serves U.S. interventionalists and markets its product, CGuard Prime, primarily in the U.S. and Europe. It targets growth markets and new territories, focusing on interventionalists transitioning from carotid endarterectomy (CEA) to carotid artery stenting (CAS) and transcarotid artery revascularization (TCAR). The company markets and sells CGuard Prime through a direct sales organization of approximately 30 sales and clinical support personnel in the U.S. It collaborates with leading physicians and key opinion leaders to support marketing efforts and participate in clinical studies. The company initially launched CGuard EPS in CE-marked countries in 2015 and fully launched it in Europe in September 2015, utilizing local distribution partners and internal sales initiatives to expand geographic coverage and clinical specialty reach. CGuard Prime is positioned as a second-generation stent with positive patient outcomes, with the goal of becoming the standard of care for treating carotid artery disease in the U.S. The company is also evaluating CGuard Prime in TCAR-based clinical programs, including the CGUARDIANS II pivotal trial.
Sources:
Inspiremd Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Inspiremd Inc’s corporate clients.
For your research, we’ve provided 9 tables on Inspiremd Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
127.27 %